Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance.

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-01-01 DOI:10.1080/2162402X.2023.2224672

Marine Fidelle, Ai-Ling Tian, Laurence Zitvogel, Guido Kroemer

引用次数: 0

Abstract

In a recent paper in Science, Fidelle et al. unravel a gut immune checkpoint that is subverted by antibiotic treatment. Post-antibiotic dysbiosis of the ileum causes an increase in bile acids that downregulate MAdCAM-1, thereby triggering the exodus of immunosuppressive T cells from gut-associated lymphoid tissues toward tumors.

Abstract Image

查看原文本刊更多论文

胆汁酸调节MAdCAM-1表达，将肠道微生物群与癌症免疫监测联系起来。

在《科学》杂志最近的一篇论文中，Fidelle等人揭示了被抗生素治疗破坏的肠道免疫检查点。抗生素后回肠生态失调导致胆汁酸增加，从而下调MAdCAM-1，从而引发免疫抑制T细胞从肠道相关淋巴组织向肿瘤转移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.